<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23507">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02080013</url>
  </required_header>
  <id_info>
    <org_study_id>JVS-D-14-00218</org_study_id>
    <nct_id>NCT02080013</nct_id>
  </id_info>
  <brief_title>Endovenous Radiofrequency Versus Laser Ablation for the Treatment of Great Saphenous Vein Reflux</brief_title>
  <official_title>Prospective, Randomized Study of Endovenous Segmental Radiofrequency Versus 1320 nm Laser Ablation for the Treatment of Great Saphenous Vein Reflux (RVLAb Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <authority>Saudi Arabia: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      our aim is to compare early outcomes following EVL 1320 nm and segmental RF in a randomized
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endovenous Radiofrequency versus Laser Ablation for the Treatment of Great Saphenous Vein
      Reflux
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>ClosureFast group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radiofrequency</intervention_name>
    <description>ClosureFAST</description>
    <arm_group_label>ClosureFast group</arm_group_label>
    <arm_group_label>group 1</arm_group_label>
    <other_name>ClosureFAST</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18 and 60 years with incompetent GSVs documented on
             duplex ultrasound (US; B-mode and color Doppler imaging) were eligible

        Exclusion Criteria:

          -  Exclusion criteria consisted of:

          -  Current deep vein thrombosis (DVT)

          -  Thrombus in the vein of interest

          -  Previous GSV treatment

          -  Pregnancy

          -  Known malignancy

          -  Significant arterial disease (ankle : brachial pressure index below 0â€¢8)

          -  Use of anticoagulant medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossam M. Saleh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular Surgery Department, Ain Shams University</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hossam M. Saleh</investigator_full_name>
    <investigator_title>A. Prof vascular surgery</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
